Haemonetics Stock Market Value
| HAE Stock | USD 65.78 0.88 1.32% |
| Symbol | Haemonetics |
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.227 | Earnings Share 3.45 | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Haemonetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Haemonetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Haemonetics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Haemonetics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Haemonetics or generate 0.0% return on investment in Haemonetics over 90 days. Haemonetics is related to or competes with Dentsply Sirona, Concentra Group, Warby Parker, Integer Holdings, Quidel, LeMaitre Vascular, and Bausch Health. Haemonetics Corporation, a healthcare company, provides medical products and solutions More
Haemonetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Haemonetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Haemonetics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.06 | |||
| Information Ratio | 0.0988 | |||
| Maximum Drawdown | 37.26 | |||
| Value At Risk | (3.11) | |||
| Potential Upside | 3.1 |
Haemonetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Haemonetics' standard deviation. In reality, there are many statistical measures that can use Haemonetics historical prices to predict the future Haemonetics' volatility.| Risk Adjusted Performance | 0.0901 | |||
| Jensen Alpha | 0.4799 | |||
| Total Risk Alpha | 0.2039 | |||
| Sortino Ratio | 0.2084 | |||
| Treynor Ratio | (4.70) |
Haemonetics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0901 | |||
| Market Risk Adjusted Performance | (4.69) | |||
| Mean Deviation | 1.78 | |||
| Semi Deviation | 1.53 | |||
| Downside Deviation | 2.06 | |||
| Coefficient Of Variation | 895.91 | |||
| Standard Deviation | 4.35 | |||
| Variance | 18.9 | |||
| Information Ratio | 0.0988 | |||
| Jensen Alpha | 0.4799 | |||
| Total Risk Alpha | 0.2039 | |||
| Sortino Ratio | 0.2084 | |||
| Treynor Ratio | (4.70) | |||
| Maximum Drawdown | 37.26 | |||
| Value At Risk | (3.11) | |||
| Potential Upside | 3.1 | |||
| Downside Variance | 4.25 | |||
| Semi Variance | 2.35 | |||
| Expected Short fall | (1.93) | |||
| Skewness | 6.15 | |||
| Kurtosis | 45.46 |
Haemonetics Backtested Returns
Haemonetics appears to be very steady, given 3 months investment horizon. Haemonetics holds Efficiency (Sharpe) Ratio of 0.12, which attests that the entity had a 0.12 % return per unit of risk over the last 3 months. By evaluating Haemonetics' technical indicators, you can evaluate if the expected return of 0.52% is justified by implied risk. Please utilize Haemonetics' Risk Adjusted Performance of 0.0901, downside deviation of 2.06, and Market Risk Adjusted Performance of (4.69) to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Haemonetics holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of -0.1, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Haemonetics are expected to decrease at a much lower rate. During the bear market, Haemonetics is likely to outperform the market. Please check Haemonetics' total risk alpha, value at risk, and the relationship between the standard deviation and treynor ratio , to make a quick decision on whether Haemonetics' current trending patterns will revert.
Auto-correlation | -0.61 |
Very good reverse predictability
Haemonetics has very good reverse predictability. Overlapping area represents the amount of predictability between Haemonetics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Haemonetics price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Haemonetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.79 | |
| Residual Average | 0.0 | |
| Price Variance | 39.59 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Haemonetics Correlation, Haemonetics Volatility and Haemonetics Performance module to complement your research on Haemonetics. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Haemonetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.